Treatment Positioning in Vulvar Cancer Radiation Therapy
Impact of Treatment Positioning on Radiation Therapy RTOG Toxicity in Patients With Vulvar Cancer
1 other identifier
observational
20
1 country
1
Brief Summary
The study investigators will conduct a prospective study on patients with non-metastatic vulvar cancer who will receive radiation treatment using Volumetric Arc Therapy (VMAT) modality with curative intent. Our aim is to compare straight-leg versus frog-leg position in terms of RTOG acute skin toxicity. Also, the study investigators will evaluate if positioning has an impact on the total treatment time and deviation on Cone Beam CT (CBCT) that might warrant re-simulation and consequently re-planning.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Jul 2020
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
July 1, 2020
CompletedFirst Submitted
Initial submission to the registry
August 14, 2021
CompletedFirst Posted
Study publicly available on registry
August 20, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2025
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2025
CompletedSeptember 12, 2025
September 1, 2025
4.5 years
August 14, 2021
September 6, 2025
Conditions
Outcome Measures
Primary Outcomes (1)
RTOG acute Skin toxicity (<3 months of starting RT)
3 months after completion
Secondary Outcomes (1)
Total treatment time and the need for re-planning
3 months for each patient
Study Arms (2)
Radiation therapy in frog leg position
Radiation therapy in straight leg position
Eligibility Criteria
Women who were diagnosed with vulvar carcinoma, receiving adjuvant or definitive chemoradiation to primary disease and inguinal lymph nodes
You may qualify if:
- Age \>= 18 years
- ECOG PS = 0-1
- Women with Bx confirmed vulvar cancer FIGO stage I-IVA (treated with curative intent)
You may not qualify if:
- Patients whom radiotherapy plans do not cover inguinal lymph nodes will be excluded.
- Vulnerable patients will be excluded (pregnant)
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
King Hussein Cancer Center
Amman, Amman Governorate, 11941, Jordan
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Fawzi J Abuhijla
King Hussein Cancer Center
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
August 14, 2021
First Posted
August 20, 2021
Study Start
July 1, 2020
Primary Completion
January 1, 2025
Study Completion
January 1, 2025
Last Updated
September 12, 2025
Record last verified: 2025-09